Skip to main
STIM

Neuronetics Inc (STIM) Stock Forecast & Price Target

Neuronetics Inc (STIM) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Neuronetics is poised for continued success with its strong Q2 performance and strategic focus on improving margins and expanding its customer base through acquisitions and partnerships. However, potential competition and regulatory challenges could present risks in the future. The company's success in treating mental health conditions and its collaborations in the growing interventional psychiatry space set it up for long-term growth potential, particularly with the potential approval of COMP360 psilocybin therapy.

Bears say

Neuronetics is facing several challenges that could impact their profitability, including inconsistent commercial execution and a potential slowdown in procedure volumes. They have a history of operating losses and continue to burn significant amounts of cash, with $19M in cash at the end of Q1 and guidance implying an additional $6M in operating cash outflows for the remainder of the year. Their reliance on equity issuances and debt could also be a concern if they continue to struggle with profitability.

Neuronetics Inc (STIM) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neuronetics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neuronetics Inc (STIM) Forecast

Analysts have given Neuronetics Inc (STIM) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Neuronetics Inc (STIM) has a Strong Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neuronetics Inc (STIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.